Accelerate Diagnostics (AXDX) Projected to Post Quarterly Earnings on Wednesday

Accelerate Diagnostics (NASDAQ:AXDX) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.

Accelerate Diagnostics (NASDAQ:AXDX) last posted its earnings results on Thursday, March 20th. The medical research company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.13. The company had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $3.00 million. On average, analysts expect Accelerate Diagnostics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Accelerate Diagnostics Trading Down 10.3 %

Shares of Accelerate Diagnostics stock opened at $0.49 on Wednesday. The company’s 50-day moving average price is $0.78 and its 200-day moving average price is $1.20. Accelerate Diagnostics has a 12-month low of $0.46 and a 12-month high of $2.09. The company has a market cap of $12.35 million, a price-to-earnings ratio of -0.17 and a beta of 0.22.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Accelerate Diagnostics in a report on Sunday. They issued a “hold” rating for the company.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.